DARE logo

DAREDare Bioscience Inc

$2.16
$0.03
(1.37%)
Today
Updated: 02:54 PM EDT
Reported EarningsMay 14
Mkt Cap$32.81M
Vol60,803.00
News
all
press releases
Dare Bioscience Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
News Placeholder
More News
News Placeholder
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?
Dare Bioscience stock climbed after Phase 3 interim data for Ovaprene showed expected pregnancy rates and no trial changes by DSMB.read more...
Benzinga
News Placeholder
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +91.67% and -28.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -45.28% and -45.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of +39.91% and -21.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +26.32% and +365.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of -59.52% and +16.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>